<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEL25118-RT4-FX-GYW"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S832 IS: Ensuring Pathways to Innovative Cures Act of 2025</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-03-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 832</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250304">March 4, 2025</action-date><action-desc><sponsor name-id="S384">Mr. Tillis</sponsor> (for himself, <cosponsor name-id="S417">Mr. Budd</cosponsor>, <cosponsor name-id="S396">Mrs. Blackburn</cosponsor>, <cosponsor name-id="S375">Mr. Daines</cosponsor>, and <cosponsor name-id="S378">Mr. Lankford</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="H50089E8C08A7475E856B3A87975D861F"><section id="id0866f75313bc4bd187bf80f7f08a1ef8" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Ensuring Pathways to Innovative Cures Act of 2025</short-title></quote> or the <quote><short-title>EPIC Act of 2025</short-title></quote>.</text></section><section section-type="subsequent-section" id="H1773130055024BEF8C9EDC561E9881ED"><enum>2.</enum><header>Equalizing the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program</header><text display-inline="no-display-inline">Section 1192(e)(1)(A)(ii) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320f-1">42 U.S.C. 1320f–1(e)(1)(A)(ii)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="id43345c7713bc4762b0382be248f306bc"><enum>(1)</enum><text>by striking <quote>year, at least 7</quote> and inserting “year—</text><quoted-block style="OLC" display-inline="no-display-inline" id="idE32E736CDB1E43B592839581C7E69B3A"><subclause commented="no" display-inline="no-display-inline" id="id4332f75707564f2a8b473ebe188fadef"><enum>(I)</enum><text>for initial price applicability years 2026 and 2027, at least 7</text></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3e1bf43510f94387b6c8b45cbf53f146"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id4CA272D0747F49A6994A262519258C2F"><subclause id="id421440c953bc49e7965a5f9f4c3f7ef9"><enum>(II)</enum><text>for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and</text></subclause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

